JNJ-38158471（Cat No.:I015026）is an oral, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor developed for oncology research. By blocking VEGFR-2–mediated angiogenesis, it disrupts tumor vascularization, nutrient supply, and growth. Preclinical and early clinical studies demonstrated its ability to inhibit endothelial cell proliferation and tumor progression, with manageable safety profiles. JNJ-38158471 shows particular promise in solid tumor models, including colorectal, breast, and lung cancers. Its potent and specific action against VEGFR-2 makes it a valuable experimental compound for studying anti-angiogenic cancer therapies and tumor microenvironment modulation.